9
02 Janusz M. D a˛ browski et al.
Acknowledgements—This work has been supported in part by the
Polish Ministry of Science and Higher Education (Grant No.
1
˜
283 ⁄ T09 ⁄ 1005 ⁄ 29), Funda c¸ ao para a Ci eˆ ncia e Tecnologia and
FEDER (Project No. POCTI ⁄ QUI ⁄ 555505 ⁄ 2004).
REFERENCES
1
. Detty, M. R., S. L. Gibson and S. J. Wagner (2004) Current
clinical and preclinical photosensitizers for use in photodynamic
therapy. J. Med. Chem. 47, 3897–3915.
2
. Castano, A. P., T. N. Demidowa and M. R. Hamblin (2004)
Mechanisms in photodynamic therapy: Part I—photosensitisers,
photochemistry and cellular localization. Photodiagn. Photodyn.
Ther. 1, 279–293.
Figure 6. Control S-91 untreated cells (left picture) and PDT treated
S-91 cells (20 lM of TCPPSO
3
H irradiated at 6.2 J cm) ) 24 h after
treatment (right picture).
2
3
4
5
. Stochel, G., A. Wanat, E. Kulis and Z. Stasicka (1998) Light
and metal complexes in medicine. Coord. Chem. Rev. 171, 203–
2
20.
. Ochsner, M. (1997) Photophysical and photobiological processes
in the photodynamic therapy of tumors. J. Photochem. Photobiol.
B 39, 1–18.
. Szaciowski, K., W. Macyk, A. Drzewiecka-Matuszek, M. Brindell
and G. Stochel (2005) Bioinorganic photochemistry. Frontiers and
mechanisms. Chem. Rev. 105, 2647–2694.
inhibits lipid peroxidation (35). SKMEL 188 cells, with higher
melanin level were slightly less sensitive. Interestingly, MCF 7
malignant breast cancer cells were the least sensitive to
photodynamic action in the presence of TCPPSO H. Light
3
)2
doses up to 1 J cm caused only slightly toxic effects towards
the three tested cell lines. Light doses from 1 to 3 J cm)
inhibited 50% cell proliferation, while doses higher than
6. Bonnet, R. (2000) Chemical Aspects of Photodynamic Therapy,
Vol. 1, Gordon and Breach Science Publishers, Amsterdam.
2
7
. Sharman, W. M., C. M. Allen and J. E. van Lier (1999) Photo-
dynamic therapeutics: Basic principles and clinical applications.
Drug Discov. Today 4, 507–517.
)2
4
(
J cm
Table 3). In conclusion, photocytotoxicity of TCPPSO
decreased the surviving fraction down to 10%
3
H
8. Allison, R. R., G. H. Downie, R. Cuenca, X.-H. Hu, C. Childs and
C. H. Sibata (2004) Photosensitizers in clinical PDT. Photodiagn.
Photodyn. Ther. 1, 27–42.
was proportional to the irradiation dose as can be seen in
Fig. 4.
9
. Luksiene, Z. (2003) Photodynamic therapy: Mechanism of action
and ways to improve the efficiency of treatment. Medicina 12,
3
What is more, all PDT treated (TCPPSO H 20 lM and
)2
light dose of 6.2 J cm ) S-91 cells were dead 24 h after
treatment as can be seen in Fig. 6.
1137–1150.
10. Dolmans, D. E., D. Fukumura and R. K. Jain (2003) Photody-
namic therapy for cancer. Nat. Rev. Cancer 3, 380–387.
1
1. Nyman, E. S. and P. H. Hynninen (2004) Research advances in the
use of tetrapyrrolic photosensitizers for photodynamic therapy.
J. Photochem. Photobiol. B 73, 1–28.
CONCLUSIONS
Water-soluble 5,10,15,20–tetrakis(2-chloro-3-sulfonylphenyl)
12. O’Riordan, K., O. E. Akilov and T. Hasan (2005) The potential
for photodynamic therapy in the treatment of localized infections.
Photodiagn. Photodyn. Ther. 2, 247–262.
3
porphyrin (TCPPSO H) can be readily synthesized from
economical starting materials. Its absorption band at 633 nm
does not have a particularly high absorption coefficient but its
photodynamic action is still remarkable for PDT because of its
long triplet lifetime and high singlet oxygen quantum yield.
1
3. Tome, J., M. Neves, A. Tome, J. Cavaleiro, M. Soncin, M.
Magaraggia, S. Ferro and G. Jori (2004) Synthesis and antibac-
terial activity of new poly-Ss-lysine-porphyrin conjugates. J. Med.
Chem. 47, 6649–6652.
1
4. Mironov, A. F., A. S. Seylanov, J. A. Seylanov, V. M. Pizhik, I. V.
Derughenko and A. J. Nockel (1992) Haematoporphyrin deriva-
tives: Distribution in a living organism. J. Photochem. Photobiol. B
Biol. 16, 341.
Furthermore, TCPPSO H is soluble in water, is not very prone
3
3
to aggregate and is photochemically stable. TCPPSO H
combines these chemical and photochemical properties with
a low toxicity in the dark and a tendency to accumulate in all
tested cell lines. The light doses required to destroy 90% of
15. Mori, M., I. Sakata, T. Hirano, A. Obana, S. Nakajima, M.
Hikida and T. Kumagai (2000) Photodynamic therapy for
experimental tumors using ATX-S10(Na), a hydrophilic chlorin
photosensitizer, and diode laser. Jpn. J. Cancer Res. 91, 753–759.
S91, SKMEL 188 and MCF7 cells are 4, 5.4 and 6.3 J cm)
2
,
respectively. These accentuated photocytotoxicities and our
previous study (22,23) reveal that halogenated water-soluble
porphyrins and their dihydro and tetrahydro derivatives are
promising candidates for a new PDT-agent and are worth
further investigations, especially in vivo.
1
6. Tanielian, C., C. Schweitzer, R. Mechin and C. Wolff (2001)
Quantum yield of singlet oxygen production by monomeric and
aggregated forms of hematoporphyrin derivative. Free Radic. Biol.
Med. 30, 208–212.
1
7. Pineiro, M., A. M. d’A. Rocha Gonsalves, M. M. Pereira,
S. J. Formosinho and L. G. Arnaut (2002) New halogenated
bacteriochlorins and their efficiency in singlet-oxygen sensitiza-
tion. J. Phys. Chem. 106, 3787–3795.
This study also revealed some differences and a lack of
correlation between the cellular uptake of the photosensitizer
(
TCPPSO H) and the photodynamic responses observed for
3
18. Pineiro, M., M. M. Pereira, A. M. d’A. Rocha Gonsalves,
L. G. Arnaut and S. J. Formosinho (2001) Singlet oxygen
quantum yields from halogenated chlorins: Potential new
photodynamic therapy agents. J. Photochem. Photobiol. A 138,
SKMEL 188 and MCF7 cell lines. The lack of correlation
between cellular uptake, intracellular concentration and phot-
odynamic efficiency in cells with different histologies as well as
in cells from tumors of different origins has been reported in
1
19. MacDonald, J. and T. J. Dougherty (2001) Basic principles of
47–157.
photodynamic therapy. J. Porphyrins Phthalocyanines 5, 105–129.
0. Sternberg, E. D. and D. Dolphin (1998) Porphyrin-based photo-
3
the literature (36). The cellular uptake of TCPPSO H depends
2
on cell characteristics including cell volume, state of prolifer-
ation, cell type and other factors (e.g. presence of melanin in
cells).
sensitizers for use in photodynamic therapy. Tetrahedron 54,
4
151–4202.